Xylazine awareness and attitudes among people who use drugs in Ohio, 2023-2024.
Drug testing
Fentanyl
Ohio
Overdose
Xylazine
Journal
Harm reduction journal
ISSN: 1477-7517
Titre abrégé: Harm Reduct J
Pays: England
ID NLM: 101153624
Informations de publication
Date de publication:
14 Oct 2024
14 Oct 2024
Historique:
received:
23
07
2024
accepted:
01
10
2024
medline:
15
10
2024
pubmed:
15
10
2024
entrez:
14
10
2024
Statut:
epublish
Résumé
The prevalence of xylazine, a non-opioid tranquilizer not for human consumption, in illicitly manufactured fentanyl is increasing in the United States. However, little is known about xylazine awareness and attitudes among people who use drugs. A cross-sectional survey of people who use drugs in Ohio was conducted from November 2023 - May 2024 to identify xylazine awareness and attitudes in rural and urban counties across the state. Study participants were recruited from naloxone distribution sites, including health departments, syringe service programs, and community-based organizations. Among 630 people who use drugs in Ohio, more than one-half (53.5%) were unaware of xylazine being in "street drugs," regardless of urbanicity. Among individuals who were aware of xylazine, most (73.0%) indicated they did not want to use the drug and try to avoid it. In addition, 75.8% of this group felt it was "very" or "extremely" important to know if xylazine was in their drugs. This research found that many people who use drugs in Ohio are unaware of xylazine and its risks. An important finding of this study is that most individuals who had heard of xylazine did not want to use it and were concerned about knowing whether xylazine was in their drugs.
Sections du résumé
BACKGROUND
BACKGROUND
The prevalence of xylazine, a non-opioid tranquilizer not for human consumption, in illicitly manufactured fentanyl is increasing in the United States. However, little is known about xylazine awareness and attitudes among people who use drugs.
METHODS
METHODS
A cross-sectional survey of people who use drugs in Ohio was conducted from November 2023 - May 2024 to identify xylazine awareness and attitudes in rural and urban counties across the state. Study participants were recruited from naloxone distribution sites, including health departments, syringe service programs, and community-based organizations.
RESULTS
RESULTS
Among 630 people who use drugs in Ohio, more than one-half (53.5%) were unaware of xylazine being in "street drugs," regardless of urbanicity. Among individuals who were aware of xylazine, most (73.0%) indicated they did not want to use the drug and try to avoid it. In addition, 75.8% of this group felt it was "very" or "extremely" important to know if xylazine was in their drugs.
DISCUSSION
CONCLUSIONS
This research found that many people who use drugs in Ohio are unaware of xylazine and its risks. An important finding of this study is that most individuals who had heard of xylazine did not want to use it and were concerned about knowing whether xylazine was in their drugs.
Identifiants
pubmed: 39402530
doi: 10.1186/s12954-024-01097-5
pii: 10.1186/s12954-024-01097-5
doi:
Substances chimiques
Xylazine
2KFG9TP5V8
Illicit Drugs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
182Subventions
Organisme : National Institute on Drug Abuse of the National Institutes of Health
ID : R01DA052580
Organisme : National Institute on Drug Abuse of the National Institutes of Health
ID : R01DA052580
Organisme : National Institute on Drug Abuse of the National Institutes of Health
ID : R01DA052580
Organisme : National Institute on Drug Abuse of the National Institutes of Health
ID : R01DA052580
Informations de copyright
© 2024. The Author(s).
Références
United State Drug Enforcement Administration [internet]. Statement from DEA Administrator Anne Milgram on the Increase in DEA Fentanyl Seizures Containing Xylazine. https://www.dea.gov/documents/2024/2024-04/2024-04-26/statement-dea-administrator-anne-milgram-increase-dea-fentanyl . Accessed 12 June 2024.
National Institute on Drug Abuse, National Institutes of Health [internet]. Xylazine. https://nida.nih.gov/research-topics/xylazine#references . Accessed 12 June 2024.
Chhabra N, Mir M, Hua MJ, Berg S, Nowinski-Konchak J, Aks S, Arunkumar P. Xylazine related deaths – Cook County Illinois, 2017–2021. MMWR. 2022;71:503–4.
pubmed: 35358161
pmcid: 8979597
Korn WR, Stone MD, Haviland KL, Toohey JM, Stickle DF. High prevalence of xylazine among fentanyl screen-positive urines from hospitalized patients, Philadelphia, 2021. Clin Chim Acta. 2021;521:151–154. https://doi.org/10.1016/j.cca.2021.07.010 . Epub 2021 Jul 12. PMID: 34265257.
Choi S, Irwin MR, Kiyatkin EA. Xylazine effects on opioid-induced brain hypoxia. Psychopharmacology. 2023;240(7):1561–71. https://doi.org/10.1007/s00213-023-06390-y . Epub 2023 Jun 21. PMID: 37340247.
doi: 10.1007/s00213-023-06390-y
pubmed: 37340247
pmcid: 10775769
Ruiz-Colón K, Chavez-Arias C, Díaz-Alcalá JE, et al. Xylazine intoxication in humans and its importance as an emerging adulterant in abused drugs: a comprehensive review of the literature. Forensic Sci Int. 2014;240:1–8.
doi: 10.1016/j.forsciint.2014.03.015
pubmed: 24769343
Smith MA, Biancorosso SL, Camp JD, Hailu SH, Johansen AN, Morris MH, Carlson HN. Tranq-Dope Overdose and Mortality: Lethality Induced by Fentanyl and Xylazine. bioRxiv [Preprint]. 2023 Sep 26:2023.09.25.559379. https://doi.org/10.1101/2023.09.25.559379 . PMID: 37808678; PMCID: PMC10557575.
Hays HL, Spiller HA, DeRienz RT, Rine NI, Guo HT, Seidenfeld M, Michaels NL, Smith GA. Evaluation of the relationship of xylazine and fentanyl blood concentrations among fentanyl-associated fatalities. Clin Toxicol (Phila). 2024;62(1):26–31. Epub 2024 Feb 14. PMID: 38353935.
doi: 10.1080/15563650.2024.2309326
pubmed: 38353935
Love JS, Levine M, Aldy K, Brent J, Krotulski AJ, Logan BK, Vargas-Torres C, Walton SE, Amaducci A, Calello D, Hendrickson R, Hughes A, Kurt A, Judge B, Pizon A, Schwarz E, Shulman J, Wiegan T, Wax P, Manini AF. Opioid overdoses involving xylazine in emergency department patients: a multicenter study. Clin Toxicol (Phila). 2023;61(3):173–80. PMID: 37014353; PMCID: PMC10074294.
doi: 10.1080/15563650.2022.2159427
pubmed: 37014353
García MG, Pérez-Cárceles MD, Osuna E, Legaz I. Drug-facilitated sexual assault and other crimes: a systematic review by countries. J Forensic Leg Med. 2021;79:102151. https://doi.org/10.1016/j.jflm.2021.102151 .
doi: 10.1016/j.jflm.2021.102151
pubmed: 33773270
Wei J, Wachuku C, Berk-Krauss J, Steele KT, Rosenbach M, Messenger E. Severe cutaneous ulcerations secondary to xylazine (tranq): a case series. JAAD Case Rep. 2023;36:89–91. https://doi.org/10.1016/j.jdcr.2023.04.016 . PMID: 37274146; PMCID: PMC102324.
doi: 10.1016/j.jdcr.2023.04.016
pubmed: 37274146
pmcid: 10232457
United States Drug Enforcement Administration. Public Safety Alert. DEA reports widespread threat of fentanyl mixed with xylazine. https://www.dea.gov/alert/dea-reports-widespread-threat-fentanyl-mixed-xylazine . Accessed 18 September 2024.
Kariisa M, O’Donnell J, Kumar S, Mattson CL, Goldberger BA. MMWR Morb Mortal Wkly Rep. 2023;72(26):721–7. https://doi.org/10.15585/mmwr.mm7226a4 . PMID: 37384558; PMCID: PMC10328484. Illicitly Manufactured Fentanyl-Involved Overdose Deaths with Detected Xylazine - United States, January 2019-June 2022.
Spencer MR, Cisewski JA, Warner M, Garnett MF. Drug overdose deaths involving xylazine: United States, 2018–2021. Vital Statistics Rapid Release; no 30. Hyattsville, MD: National Center for Health Statistics. 2023. https://doi.org/10.15620/cdc:129519
Quijano T, Crowell J, Eggert K, Clark K, Alexander M, Grau L, Heimer R. Xylazine in the drug supply: emerging threats and lessons learned in areas with high levels of adulteration. Int J Drug Policy. 2023;120:104154. https://doi.org/10.1016/j.drugpo.2023.104154 .
doi: 10.1016/j.drugpo.2023.104154
pubmed: 37574646
Zagorski CM, Hosey RA, Moraff C, Ferguson A, Figgatt M, Aronowitz S, Stahl NE, Hill LG, McElligott Z, Dasgupta N. Reducing the harms of xylazine: clinical approaches, research deficits, and public health context. Harm Reduct J. 2023;20(1):141. https://doi.org/10.1186/s12954-023-00879-7 .
doi: 10.1186/s12954-023-00879-7
pubmed: 37777769
pmcid: 10544173
Cano M, Daniulaityte R, Marsiglia F. Xylazine in overdose deaths and forensic drug reports in US States, 2019–2022. JAMA Netw Open. 2024;7(1):e2350630. https://doi.org/10.1001/jamanetworkopen.2023.50630 . PMID: 38180756; PMCID: PMC10770774.
doi: 10.1001/jamanetworkopen.2023.50630
pubmed: 38180756
pmcid: 10770774
Cauchon D. Harm Reduction Ohio [internet]. Xylazine in Ohio: ‘It’s a fentanyl thing. https://www.harmreductionohio.org/new-report-xylazine-plentiful-in-fentanyl-but-not-in-other-drugs/#:~:text=Because%20xylazine%20data%20prior%20to,how%20quickly%20its%20presence%20expanded.&text=Of%20all%2013%2C219%20drugs%20subject,3%2C563%20(27.0%25)%20contained%20fentanyl . Accessed 12 June 2024.
Short Mejia A, Smith GA, Fernandez S, Freisthler B, Grella C, Michaels NL. Evaluating fentanyl test strips as a harm reduction strategy in rural and urban counties: study protocol for a randomized controlled trial. Trials. 2024;25(1):587. https://doi.org/10.1186/s13063-024-08440-y . PMID: 39232778; PMCID: PMC11373481.
doi: 10.1186/s13063-024-08440-y
pubmed: 39232778
pmcid: 11373481
U.S. Department of Health and Human Services, Health Resources & Services Administration (HRSA). List of Rural Counties and Designated Eligible Census Tracts in Metropolitan Counties. Updated December 31. 2018. https://www.hrsa.gov/sites/default/files/hrsa/rural-health/resources/forhp-eligible-areas.pdf . Accessed 17 September 2024.
Chen W, Qian L, Shi J, Franklin M. Comparing performance between log-binomial and robust Poisson regression models for estimating risk ratios under model misspecification. BMC Med Res Methodol. 2018;18(1):63. https://doi.org/10.1186/s12874-018-0519-5 .
doi: 10.1186/s12874-018-0519-5
pubmed: 29929477
pmcid: 6013902
Barros AJ, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol. 2003;3:21. https://doi.org/10.1186/1471-2288-3-21 .
doi: 10.1186/1471-2288-3-21
pubmed: 14567763
pmcid: 521200
Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702–6. https://doi.org/10.1093/aje/kwh090 .
doi: 10.1093/aje/kwh090
pubmed: 15033648
Greenland S. Interpretation and choice of effect measures in epidemiologic analyses. Am J Epidemiol. 1987;125(5):761–68. https://doi.org/10.1093/oxfordjournals.aje.a114593 .
doi: 10.1093/oxfordjournals.aje.a114593
pubmed: 3551588
Tan M, Nassau T, Kuncio D, et al. Xylazine use among people who inject drugs, Philadelphia 2022. J Addict Med. 2024;18(2):194–200. https://doi.org/10.1097/ADM.0000000000001264 .
doi: 10.1097/ADM.0000000000001264
pubmed: 38289240
Spadaro A, O’Connor K, Lakamana S, et al. Self-reported xylazine experiences: a mixed-methods study of Reddit subscribers. J Addict Med. 2023;17(6):691–4. https://doi.org/10.1097/ADM.0000000000001216 .
doi: 10.1097/ADM.0000000000001216
pubmed: 37934533
pmcid: 10857795
Nunez J, DeJoseph ME, Gill JR. Xylazine, a Veterinary Tranquilizer, detected in 42 accidental fentanyl intoxication deaths. Am J Forensic Med Pathol. 2021;42(1):9–11. https://doi.org/10.1097/paf.0000000000000622 .
doi: 10.1097/paf.0000000000000622
pubmed: 33031124
Sacco LN, Sheikh HZ. Xylazine: Considerations for federal control. Congressional Research Service. Updated August 1, 2023. https://crsreports.congress.gov/product/pdf/IN/IN12086#:~:text=Xylazine%20is%20not%20currently%20controlled,DEA%20to%20regulate%20the%20substance . Accessed 18 September 2024.
Lampe JR. Xylazine and the Controlled Substances Act: Legal considerations for Congress. Congressional Research Service. July 19, 2024. https://crsreports.congress.gov/product/pdf/LSB/LSB11202#:~:text=on%20drug%20paraphernalia.-,Considerations%20for%20Congress,%2C%20zoo%20animals%2C%20and%20livestock . Accessed 18 September 2024.
State of Ohio Office of the Governor. Governor DeWine Authorizes Emergency Classification of Xylazine as Schedule III Controlled Substance. https://governor.ohio.gov/media/news-and-media/Governor-DeWine-Authorizes-Emergency-Classification-of-Xylazine-as-Schedule-III-Controlled-Substance . Accessed 17 September 2024.